Saturday, 7 November 2026European Markets

MAGNORA And ELMERA GROUP Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(VIANEWS) - MAGNORA (MGN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Utilities sector.

Financial Asset Price Forward Dividend Yield Return on Equity
MAGNORA (MGN.OL) kr25.90 27.96% 3.91%
ELMERA GROUP (ELMRA.OL) kr35.00 6.79% 5.02%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. MAGNORA (MGN.OL)

27.96% Forward Dividend Yield and 3.91% Return On Equity

Magnora ASA operates as a renewable energy development company in Norway, Sweden, and the United States. The company primarily focuses on developing wind, solar photovoltaic (PV), and battery storage projects. It also hold license agreements with the Dana Western Isles and Shell Penguins. It serves renewable energy operators, investment and oil companies, and global marine contractors. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr0.48.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 53.96. Meaning, the purchaser of the share is investing kr53.96 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.91%.

More news about MAGNORA.

2. ELMERA GROUP (ELMRA.OL)

6.79% Forward Dividend Yield and 5.02% Return On Equity

Elmera Group ASA, together with its subsidiaries, engages in the purchase, sale, and portfolio management of electrical power to households, private and public companies, and municipalities in Norway. The company operates through Consumer, Business, and Nordic segments. It sells electrical power and related services to private consumers, business consumers, as well as consumers in Finland and Sweden. The company also manufactures and sells EV chargers and PV panels; and provides payment solutions services. In addition, it manages, researches, and develops products and services related to electrical power; and provides mobile phone services to private customers. The company was formerly known as Fjordkraft Holding ASA and changed its name to Elmera Group ASA in April 2022. Elmera Group ASA was founded in 2001 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, ELMERA GROUP has a trailing twelve months EPS of kr1.82.

PE Ratio

ELMERA GROUP has a trailing twelve months price to earnings ratio of 19.23. Meaning, the purchaser of the share is investing kr19.23 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.02%.

More news about ELMERA GROUP.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com